Evidence map›Paper›PMID 33255452›Full record

ArticleCancers2020

KLK4 Induces Anti-Tumor Effects in Human Xenograft Mouse Models of Orthotopic and Metastatic Prostate Cancer.

Brian W-C Tse, Thomas Kryza, Mei-Chun Yeh, Ying Dong, Kamil A Sokolowski, Carina Walpole, Tobias Dreyer, Johanna Felber, Jonathan Harris, Viktor Magdolen and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Activation of the HNRNPA2B1/Journal of Cancer · 2023
    Article
  2. Consistent DNA Hypomethylations in Prostate Cancer.International journal of molecular sciences · 2022
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Brian W-C TsePreclinical Imaging Facility, Translational Research Institute, Brisbane, QLD 4102, Australia.ORCID 0000-0002-5982-8369
Thomas KryzaAustralian Prostate Cancer Research Centre-Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, QLD 4102, Australia.ORCID 0000-0003-1668-8551
Mei-Chun YehAustralian Prostate Cancer Research Centre-Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, QLD 4102, Australia.
Ying DongAustralian Prostate Cancer Research Centre-Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, QLD 4102, Australia.
Kamil A SokolowskiPreclinical Imaging Facility, Translational Research Institute, Brisbane, QLD 4102, Australia.
Carina WalpoleAustralian Prostate Cancer Research Centre-Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, QLD 4102, Australia.
Tobias DreyerClinical Research Unit, Department of Obstetrics and Gynecology, Technical University of Munich, 81675 Munich, Germany.ORCID 0000-0002-5366-7859
Johanna FelberClinical Research Unit, Department of Obstetrics and Gynecology, Technical University of Munich, 81675 Munich, Germany.
Jonathan HarrisSchool of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4102, Australia.
Viktor MagdolenClinical Research Unit, Department of Obstetrics and Gynecology, Technical University of Munich, 81675 Munich, Germany.ORCID 0000-0003-0167-793X
Pamela J RussellAustralian Prostate Cancer Research Centre-Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, QLD 4102, Australia.
Judith A ClementsAustralian Prostate Cancer Research Centre-Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, QLD 4102, Australia.
Translational Research Institute · AUTechnical University of Munich · DEQueensland University of Technology · AU

Funding

German Academic Exchange Service (DAAD) and the 445 German Research Society DFG, MA 1236/10-1U.S. Department of Defense W81XWH-14-1-0290
6 · The paper itself

Abstract

Recent reports have suggested the role of kallikrein-related peptidase 4 (KLK4) to be that of remodeling the tumor microenvironment in many cancers, including prostate cancer. Notably, these studies have suggested a pro-tumorigenic role for KLK4, especially in prostate cancer. However, these have been primarily in vitro studies, with limited in vivo studies performed to date. Herein, we employed an orthotopic inoculation xenograft model to mimic the growth of primary tumors, and an intracardiac injection to induce metastatic dissemination to determine the in vivo tumorigenic effects of KLK4 overexpressed in PC3 prostate cancer cells. Notably, we found that these KLK4-expressing cells gave rise to smaller localized tumors and decreased metastases than the parent PC-3 cells. To our knowledge, this is the first report of an anti-tumorigenic effect of KLK4, particularly in prostate cancer. These findings also provide a cautionary tale of the need for in vivo analyses to substantiate in vitro experimental data.

Indexed as

imagingkallikrein-related peptidase 4KLK4metastasisprostate cancertumor xenografts

Identifiers

PMID33255452
PMCPMC7761350
OpenAlexW3108818844

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.